Thu, March 24, 2011
Wed, March 23, 2011
Tue, March 22, 2011
Mon, March 21, 2011
[ Mon, Mar 21st 2011 ] - Market Wire
30 p.m. ET
Sun, March 20, 2011
Fri, March 18, 2011
Thu, March 17, 2011
Wed, March 16, 2011
Tue, March 15, 2011
Mon, March 14, 2011
[ Mon, Mar 14th 2011 ] - Market Wire
30 AM E.T.
Sun, March 13, 2011
Sat, March 12, 2011
Fri, March 11, 2011
[ Fri, Mar 11th 2011 ] - Market Wire
Covidien????????????????FDA??
Thu, March 10, 2011
Wed, March 9, 2011
Tue, March 8, 2011
Mon, March 7, 2011
Sat, March 5, 2011
Fri, March 4, 2011

Teva to Present at the Barclays Capital 2011 Global Healthcare Conference


//health-fitness.news-articles.net/content/2011/ .. s-capital-2011-global-healthcare-conference.html
Published in Health and Fitness on Monday, March 14th 2011 at 13:00 GMT by Market Wire   Print publication without navigation


JERUSALEM--([ BUSINESS WIRE ])--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Barclays Capital 2011 Global Healthcare Conference with Jon Congleton, SVP & General Manager, Teva Neuroscience, presenting on Wednesday, March 16, 2011 in Miami.

What:

Teva Presentation at the Barclays Capital 2011 Global Healthcare Conference

Who:

Jon Congleton, SVP & General Manager, Teva Neuroscience

When:

Wednesday, March 16, 2011 at 4:15pm ET

Where:

[ www.tevapharm.com/financial/ ] or

[ http://cc.talkpoint.com/barc002/031511a_rb/?entity=46_MGU1R3W ]

How:

Live over the Internet a" log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.


Publication Contributing Sources